CellaVision reports sales recovery with all-time high in Americas
Organic sales growth was 5.6%, EBITDA margin 27%, and CEO Steve Ferguson appointed.
See the latest news and media coverage for CellaVision. We track all announcements, press releases, and industry mentions in real time, all in one place.
Digital hematology microscopy solutions provider
cellavision.comLast updated
In short: CellaVision reported a sales recovery in Q2 2026, reaching an all-time high in the Americas and appointing Steve Ferguson as its new CEO.
Organic sales growth was 5.6%, EBITDA margin 27%, and CEO Steve Ferguson appointed.
He replaces Simon Østergaard and brings over 25 years of biotech experience.
It enables collaboration on analysis to share expertise and reduce variability. Available in CE-marked markets under EU IVDR; not FDA-approved.
Resolutions approve financial statements, dividend of SEK 2.75 per share, board elections with Zlatko Rihter as new Chairman, and share repurchase authorization.
Good morning, everyone, and thank you for joining us today. My name is Steve Ferguson, and with me is our Chief Financial Officer, Monica Jonsson...
Cellavision, which is active in systems for automatic image analysis of blood and other body fluids, reports an EBITDA result of 55 million kronor...
In today's recommendation flow, Cellavision has received a downgraded recommendation from Pareto to hold while the target price is raised. Among the other updates, ...
Detailed price information for Cellavision Ab Ord (CLVSF) from The Globe and Mail including charting and trades.
Track CellaVision and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to CellaVision and other trending companies.